Spots Global Cancer Trial Database for A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Official Title: A Phase 1, Multi-Center, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
Study ID: NCT01013818
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic, Rochester, Minnesota, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Oxford Cancer and Haematology Centre, Headington, Oxford, United Kingdom
The Institute of Cancer Research, Belmont, Sutton, Surrey, , United Kingdom
Cancer Research UK Centre, Southampton, , United Kingdom
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
